KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBIT (2016 - 2025)

Historic EBIT for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$92.9 million.

  • Halozyme Therapeutics' EBIT fell 15292.9% to -$92.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $469.0 million, marking a year-over-year decrease of 1495.43%. This contributed to the annual value of $469.0 million for FY2025, which is 1495.43% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported EBIT of -$92.9 million as of Q4 2025, which was down 15292.9% from $217.9 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBIT peaked at $217.9 million during Q3 2025, and registered a low of -$92.9 million during Q4 2025.
  • Over the past 5 years, Halozyme Therapeutics' median EBIT value was $90.7 million (recorded in 2021), while the average stood at $95.1 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' EBIT skyrocketed by 167415.45% in 2021, and later crashed by 15292.9% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBIT (Quarter) stood at $56.5 million in 2021, then soared by 31.8% to $74.5 million in 2022, then soared by 35.6% to $101.0 million in 2023, then surged by 73.7% to $175.5 million in 2024, then tumbled by 152.93% to -$92.9 million in 2025.
  • Its last three reported values are -$92.9 million in Q4 2025, $217.9 million for Q3 2025, and $202.4 million during Q2 2025.